FilingReader Intelligence
ZIM Laboratories gets Australia approval for urology drug
August 4, 2025 at 08:29 AM UTC•By FilingReader AI
ZIM Laboratories secured marketing authorization for "Tamsulosin Hydrochloride and Dutasteride Capsules" in Australia via its subsidiary, ZIMTAS. The urology product treats benign prostatic hyperplasia.
This marks ZIM's second approval in Australia, enabling commercial launch and strengthening its urology portfolio as part of global expansion strategy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:ZIMLAB•Bombay Stock Exchange
News Alerts
Get instant email alerts when ZIM Laboratories publishes news
Free account required • Unsubscribe anytime